SAVE THE DATE
July 9 & 10, 2020, 6th edition

This year, beside US, the faculty has been extended to a large panel of European key opinion leaders, achieving science from both sides of the Atlantic.
Working interactive sessions and abstract-driven programming will also be provided.

The 5th Paris Nash Meeting, Paris, France, 11/07/2019-12/07/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 9 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits TM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits
Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

CALL FOR ABSTRACTS / POSTER SESSION

The Paris Nash Meeting Scientific Committee invites authors to submit abstracts for poster presentation during the meeting. 

Abstract submission deadline for poster presentations: May 20, 2019 

Acceptance notification: June 3, 2019

Abstracts will peer reviewed and scored by the Scientific Committee 

If your abstract is accepted, you must register no later than June 15, 2019.

Unless you register by that date, your poster will not be on display during the Paris Nash Meeting.

POSTER SESSION 2018

The Paris Nash Meeting Scientific Committee invites authors to submit abstracts for poster presentation during the meeting.

The following posters have been displayed during the 4th Paris NASH Meeting:

1. Usefulness of mirnas as non-invasive biomarkers in non-alcoholic fatty liver disease (NAFLD)
   Author: Rocío Montero-Vallejo
2. Analysis of the burden and variability in the management of NAFLD patients in clinical practice
   Author: Javier Ampuero
3. Correction of intrahepatic microcirculation disorders by hepa-merz at the non-alcoholic steatohepatitis patients
   Author: Tatiana Ermolova
4. Depletion of ripk1 in hepatocytes exacerbates liver fibrosis in non-alcoholic steatohepatitis
   Author: Michel Samson
5. Duodenal mucosal resurfacing improves lipotoxic stress, mitochondrial function, aerobic metabolism and gluconeogenic drive in type 2 diabetes
   Author: Ginger deGravelle
6. Duodenal mucosal resurfacing reduces liver fat in patients with type 2 diabetes
   Author: David Maggs
7. Genetic and functional analysis of FGF21 in NAFLD/NASH
   Author: Rocío Gallego-Durán
8. Influence of gender and liver fibrosis on the quality of life in patients with NAFLD
   Author: Jesús Funuyet-Salas
9. Interobserver concordance in controlled attenuation parameter measurement by transient elastography
   Author: Lamia Kallel
10. Nuclear factor of activated t-cells (nfatc1) signaling in steatosis and inflammation of the liver
    Author: Muhammad Umair Latif
11. Optimal triage algorithms to identify patients with NASH+NAS≥4+F≥2Mafa
    Author: Magali Sasso
12. Serum bile acids are markedly elevated in patients with compensated cirrhosis due to nash
    Author: Vlad Ratziu
13. Prevelance of hepatic steatosis diagnosed with cap-enabled transient elastography in tunisian patients with liver disease
    Author: Lamia Kallel

Congratulations to the 2018 Best Poster Presentations Awardees :

1. Ginger deGravelle, Internal Medicine, VCU Health, Richmond, Virginia, USA, “DUODENAL MUCOSAL RESURFACING IMPROVES LIPOTOXIC STRESS, MITOCHONDRIAL FUNCTION, AEROBIC METABOLISM AND GLUCONEOGENIC DRIVE IN TYPE 2 DIABETES”
2. Muhammad Umair Latif, Clinic for Gastroenterology und gastrointestinal Oncology, UMG, Goettingen, Germany, “NUCLEAR FACTOR OF ACTIVATED T-CELLS (NFATC1) SIGNALING IN STEATOSIS AND INFLAMMATION OF THE LIVER”